Teva Pharmaceutical Industries (NYSE:TEVA) Releases FY 2025 Earnings Guidance

Teva Pharmaceutical Industries (NYSE:TEVA) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided EPS guidance of 2.350-2.650 for the period, compared to the consensus EPS estimate of 2.780. The company issued revenue guidance of $16.8 billion-$17.4 billion, compared to the consensus revenue estimate of $17.1 billion.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on TEVA. UBS Group lifted their price target on Teva Pharmaceutical Industries from $28.00 to $30.00 and gave the company a “buy” rating in a research report on Thursday, January 23rd. StockNews.com lowered shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. Piper Sandler lifted their price target on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research note on Friday, January 17th. Barclays boosted their price target on shares of Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 18th. Finally, JPMorgan Chase & Co. lifted their price objective on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a report on Monday, October 21st. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $22.63.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA stock opened at $21.57 on Wednesday. The firm has a market cap of $24.43 billion, a P/E ratio of -25.37, a P/E/G ratio of 1.11 and a beta of 0.73. The business’s 50 day moving average price is $19.94 and its 200-day moving average price is $18.47. Teva Pharmaceutical Industries has a fifty-two week low of $11.48 and a fifty-two week high of $22.80. The company has a debt-to-equity ratio of 2.57, a quick ratio of 0.61 and a current ratio of 0.89.

Insider Activity

In other news, EVP Christine Fox sold 19,388 shares of the company’s stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the sale, the executive vice president now directly owns 44,104 shares in the company, valued at $744,034.48. This represents a 30.54 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Roberto Mignone sold 286,000 shares of the firm’s stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $22.01, for a total value of $6,294,860.00. Following the completion of the transaction, the director now directly owns 695,000 shares in the company, valued at $15,296,950. This trade represents a 29.15 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.